Ashiqul Haque is an accomplished biochemist with over a decade of experience in mRNA-based drug development. He earned his PhD from the University of Tübingen in collaboration with CureVac and TriLink, focusing on mRNA-based gene supplementation and correction therapy for Cystic Fibrosis. His research has led to multiple first-author publications in high-impact journals, including Molecular Therapy and Nature Communications, and he is the inventor on several patents covering chemical modifications of mRNA and lipid/LNP library creation for RNA-based therapeutics. Currently serving as CSO at Quantoom, Ashiqul plays a central role in guiding the company’s mRNA and saRNA programs for both vaccination and therapeutic applications. He oversees the full technical and scientific pipeline—from molecular design (antigen, mRNA, and plasmid engineering) to drug substance development (self-amplifying RNA formulated in lipid nanoparticles)—ensuring every stage meets rigorous innovation and quality standards. Ashiqul’s blend of deep scientific expertise, patent-backed innovation, and strategic project leadership continues to drive forward the next generation of RNA-based medicines.